Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13673958 | 0.86 | CYP2C19 (0.54) | CYP2C19ALDH1A1HTTHPGDSMN1; SMN2 | |
| SCHEMBL8283798 | 0.86 | CYP2C19 (0.57) | CYP2C19ALDH1A1HTTHPGDSMN1; SMN2 | |
| SCHEMBL13673945 | 0.85 | CYP2C19 (0.52) | CYP2C19ALDH1A1HTTHPGDSMN1; SMN2 | |
| SCHEMBL8283812 | 0.85 | PGR (0.55) | CYP2C19ALDH1A1HTTHPGDSMN1; SMN2 | |
| SCHEMBL4425797 | 0.84 | CYP2C19 (0.42) | CYP2C19ALDH1A1HTTHPGDSMN1; SMN2 | |
| SCHEMBL11644246 | 0.84 | CYP2C19 (0.60) | CYP2C19ALDH1A1HTTHPGDSMN1; SMN2 | |
| SCHEMBL4420855 | 0.82 | CYP2C19 (0.50) | CYP2C19ALDH1A1HTTMAOB | |
| SCHEMBL13706913 | 0.81 | CYP11B2 (0.49) | CYP2C19ALDH1A1HTTMAOBMAOA | |
| SCHEMBL8283632 | 0.81 | PGR (0.58) | CYP2C19ALDH1A1HTTPOLBPGR | |
| SCHEMBL13707021 | 0.80 | ALDH1A1 (0.49) | CYP2C19ALDH1A1HTTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598384-B2 | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-10-06 | — | — | US | disclosed |
| US-20090227582-A1 | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-09-10 | — | — | US | disclosed |
| US-7550482-B2 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-06-23 | — | — | US | disclosed |
| WO-2005082856-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227582-A1 | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors | GRM1, GRM5, GRM2 | CYP2C19 3590/4885ALDH1A1 2587/4885HTT 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.